logo
Your Brain On Risk: It's Not Good

Your Brain On Risk: It's Not Good

Forbes09-05-2025
MRI Brain Scan
A college student once walked into my office, brimming with excitement. 'I want to invest in Bitcoin!' he declared. When I asked why, he said, 'My roommates are making so much money. They bought it last year and it has already doubled!" This type of enthusiasm is common, but troubling. One of the key distinctions between a novice and a seasoned investor is how they understand and respond to risk. This student was acting like a novice, in that the pursuit and thrill of easy money was overshadowing their ability to seriously consider risk.
But what does it really mean to consider risk?
Traditionally, investors use statistical tools to calculate risk, like standard deviation, volatility, beta, and downside deviation, to name a few.
For instance, a stock with a historical return of 10% and a 20% standard deviation would be expected to return anywhere between -30% and +50% about 95% of the time. The higher the deviation, the more unpredictable the investment.
Mature investors consider the standard deviation alongside the return potential of an investment and then aim to maximize their risk-adjusted returns. A simple way to do this would be to seek to build a portfolio that has the highest amount of return potential given the lowest amount of estimated risk. A common way to measure risk-adjusted returns is by using the Sharpe ratio. This ratio is expected return over expected risk and tells you how much return you're earning for every unit of risk you're taking.
But is calculating risk-adjusted returns, and properly considering the risk of an investment before you buy something, the only important factor for a mature investor regarding risk?
No.
I've always believed there's more to risk than spreadsheets and ratios. Risk isn't just something we calculate, it's something we experience. It has the power to shape who we become.
When I was 15, I bought my first stock and watched it rise. The rise in every stock I bought coincided with a rise in a very delicious feeling of euphoria. Scientists call this feeling dopamine. While dopamine is fun to experience, unfortunately, it is wildly addictive. The more shots of dopamine I was experiencing over time, the more my brain was being formed and transformed from a cautious teen into someone who actively sought out risk. My brain was being rewired.
Neuroscientists have documented this. One study titled 'Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity' showed how dopamine alters the brain's reward system, pushing individuals toward greater risk-seeking behavior.
In extreme cases, this pattern mirrors gambling addiction, which is widely regarded as one of the hardest addictions to overcome. Once risk becomes tied to identity, it's no longer about strategy; it's about chasing a feeling that changes our brain.
This isn't just a theory. It's a pattern we see in culture today.
Easy gains over the last decade have created a new breed of investor: one that starts with meme stocks, moves to crypto, and ends up speculating on NFTs, sports, or more and more exotic types of new entertainment. These are markets where risk isn't just high, it's often unknowable.
And when risk becomes unknowable, you're not investing, you're gambling.
My wife experienced the opposite end of the spectrum. She bought a townhouse in 2007, just before the crash. The financial loss left her extremely risk-averse, even after the markets recovered. Her brain, like mine, was shaped by her experience, but in a different direction. She experienced so much pain that her brain actively sought to eliminate risk and she became overly-risk avoidant, which is another type of problematic financial behavior.
To truly evaluate risk, we must do two things:
If an investment's risk can't be calculated (hello, crypto and NFTs), it's probably a poor fit, especially for business owners who value sustainability, not speculation.
Whenever my students ask about investing in Bitcoin, I ask them, 'Will it change you?' Most assume wealth won't alter who they are. But research on lottery winners shows the opposite: fast money often leads to long-term dissatisfaction and compulsive behavior.
Here are two simple tips to avoid being reshaped by risk:
Long-term investors who bought and held diversified portfolios have quietly built wealth. Meanwhile, countless others who chased hot tips and quick wins are broke, both financially and emotionally.
The Bible puts it plainly:
In the end, I recommend the boring path, like my Nana, who bought a simple portfolio of high-quality stocks and forgot about it until retirement. That quiet, patient approach gave her what she needed, when she needed it, without putting her brain, or her life, at risk.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Opendoor stock pops 10% as company says CEO will step down
Opendoor stock pops 10% as company says CEO will step down

Yahoo

time12 minutes ago

  • Yahoo

Opendoor stock pops 10% as company says CEO will step down

Opendoor Technologies (OPEN) shares spiked as 8% in early trading Friday after the company announced that CEO Carrie Wheeler will step down, effective immediately. The company's board appointed Opendoor's chief technology and product officer Shrisha Radhakrishna as president and interim leader of the company. Opendoor, which uses iBuyer real estate technology to flip homes, said it was searching for a new CEO. Since going public through a SPAC transaction in 2020, Opendoor has yet to post a profitable quarter. The company received a warning in May that it faced potential delisting from the Nasdaq after trading under $1 for more than 30 days. Shares have surged more than 200% in the past month, powered in part by Carvana (CVNA) turnaround spotter EMJ Capital and speculative investors on Reddit's wallstreetbets, a haven for meme stocks. EMJ Capital founder and president Eric Jackson said in an X post on July 14 that his firm was taking a long position in Opendoor, which was then trading under $1 per share. "The communication on the earnings call from the CEO and the CFO was really awful," Jackson told Yahoo Finance last week. Jackson has been critical of Opendoor's top leadership, most recently following the company's latest quarterly results in early August, when the stock sank 20% following disappointing earnings forecast. Year-to-date Opendoor shares are up 100%. Sign in to access your portfolio

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

Yahoo

time12 minutes ago

  • Yahoo

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

Why would Trump and Intel want to work together: Opening Bid top takeaway
Why would Trump and Intel want to work together: Opening Bid top takeaway

Yahoo

time12 minutes ago

  • Yahoo

Why would Trump and Intel want to work together: Opening Bid top takeaway

Investors are in wait-and-see mode. Fed watchers have had quite a week, getting a hot Producer Price Index, a tame Consumer Price Index, and solid retail sales data out today. As it stands, markets are still betting on that September rate cut from the Jerome Powell-led Federal Reserve. There have been a few earnings stumbles in CoreWeave (CRWV), Applied Materials (AMAT), and Cava (CAVA), but a few bright spots from the likes of Cisco (CSCO). The Bullish (BLSH) IPO saw an enthusiastic response. And now markets cast their gaze to the highly anticipated meeting today between President Trump and his Russian counterpart, Vladimir Putin. The outcome of this meeting could have a host of surprises that bullish investors haven't even thought about! Stock analysis: Intel The Trump administration is reportedly in talks to have the US government take a stake in Intel (INTC). An Intel spokesperson didn't comment directly on this to me, but offered this: "Intel is deeply committed to supporting President Trump's efforts to strengthen U.S. technology and manufacturing leadership. We look forward to continuing our work with the Trump Administration to advance these shared priorities, but we are not going to comment on rumors or speculation.' The questions here are numerous. Why would the administration even want a stake in an Intel that is far behind chief rivals Nvidia (NVDA) and Advanced Micro Devices (AMD)? I encourage Trump to compare Nvidia's earnings report on Aug. 27 to the last disaster from Intel a few weeks ago. The president isn't known to hitch his ride to losers. Intel has been a loser and may stay that way in the chip game for some time. Then again, why would Intel want to get in bed with the government when embattled CEO Lip-Bu Tan and the board must act quickly to reorganize the company? I find it hard to believe the government will be a quiet minority shareholder! Intel has billions in cash and doesn't need the money that comes with terms from any government deal. There is a lot at stake here, as Intel should be a beacon of US chip-making, not the punching bag in tech circles. The company's financials have taken a major hit, with sales down for more than three straight years and earnings evaporating in the process. "[A stake would] be a big step for Intel, but right now Intel is on a horse and buggy compared to the Godfather of AI Jensen [Huang] and Nvidia," Wedbush tech analyst Dan Ives told me. Roundtable analysis: More tech When a Wall Street analyst who has been a bear on a stock for a while suddenly issues an upgrade, it always catches my attention. Today, we have that situation on Salesforce (CRM). DA Davidson analyst Gil Luria lifted his rating on Salesforce to Neutral from Underperform. Luria said investor sentiment has declined sharply on Salesforce in recent months as questions mount around the company's acquisition strategy and near-term margins. But what may not be factored into the stock is new activist investor activity, Luria said. Luria pointed out that noted activist investor Starboard Value — led by Jeff Smith — increased its stake in Salesforce by 47% this quarter, according to new 13F filings. Starboard pushed for big changes at Salesforce three years ago, which ultimately led to a new focus on margin expansion by CEO and co-founder Marc Benioff. Luria said, "We believe this is a signal there will be another round of investor activism and increased pressure on management to refocus on growth of the core business, additional margin expansion and hold off on dilutive M&A." Meanwhile, Warren Buffett's Berkshire Hathaway sold 20 million shares of Apple (AAPL) during the period, according to a new 13F filing. Berkshire's Apple holdings remain its largest equity stake by market value, despite dropping by about $9.2 billion in the second quarter. Is Buffett signaling he is concerned about Apple's tariff exposure? Perhaps. After all, Apple did warn tariffs would hit its profits by $1.1 billion in the current quarter. Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store